Azmasol Bexicap

Description
Azmasol® Bexicap capsule contains Salbutamol (as Salbutamol sulphate BP) as the
active ingredient which is a ß2‐adrenoceptor agonist used in the treatment of
asthma and other forms of diffuse reversible airways obstruction.
Indication
Azmasol® Bexicap (Salbutamol) dry powder inhaler is indicated for the treatment
and prophylaxis of bronchial asthma and for the treatment of reversible airways
obstruction associated with bronchitis and emphysema. Azmasol® Bexicap
(Salbutamol) inhaler may be used to relieve attacks of acute dyspnoea and may also
be taken prophylactically before exertion or to prevent exercise‐induced asthma.
It is suitable for treating bronchospasm in patients with coexisting heart disease or
hypertension, including those taking beta blockers, because of its selective action on
the bronchial receptors and lack of effects on the cardiovascular system. Salbutamol
is a sympathomimetic agent which has a highly selective action on beta adrenergic
receptors in bronchial muscle. At therapeutic levels, it has little effect on cardiac
receptors.
Dosage
Adults: For the relief of acute bronchospasm and for managing intermittent
episodes of asthma: 200 ‐ 400 mcg (one or two Bexicap capsules) as a single dose;
for chronic maintenance or prophylactic therapy: 200 ‐ 400 mcg (one or two
Bexicap capsules) three or four times daily; for prevention of exercise induced
bronchospasm: 400 mcg (two Bexicap capsules) before exertion.
Children: for relief of acute bronchospasm, management of episodic asthma and for
prevention of exercise induced bronchospasm: 200 mcg (one Bexicap capsule ); for
routine maintenance and prophylaxis: 200 mcg (one Bexicap capsule) three or four
times daily,
Elderly: The dosage is the same as that for adults.
Contraindications
Although intravenous Salbutamol, and occasionally Salbutamol tablets, are used in
the management of premature labour uncomplicated by conditions such as placenta
praevia, ante‐partum haemorrhage or toxaemia of pregnancy, Salbutamol inhaler
preparations are not appropriate for managing premature labour. Salbutamol
preparation should not be used for threatened abortion during the first or second
trimesters of pregnancy. Salbutamol inhaler is contraindicated in patients with a
history of hypersensitivity to any of its components.
Precautions
In the event of previously effective dose of Salbutamol dry powder inhaler failing to
give relief for at least three hours, the patient should be advised to seek medical
advice in order that any necessary additional steps may be taken. Salbutamol should
be administered cautiously to patients suffering from thyrotoxicosis.
Side Effects
Mild tremor and headache have been rarely reported. These usually disappear with
continuous treatment. There have been very rare reports of transient muscle cramp.
Hypersensitivity reactions including angioedema, urticaria, bronchospasm,
hypotension and collapse have been reported very rarely.
As with other inhalation therapy, the potential for paradoxical bronchospasm
should be kept in mind. If it occurs, the preparation should be discontinued
immediately and alternative therapy should be instituted.
Pharmaceutical Precautions
Bexicap must not be swallowed. Only to be used with Bexihaler.
Avoid storage in direct sunlight or heat.
Store below 30°C.
Keep away from children.
Remove Bexicap capsule from the blister pack only immediately before use it in the
Bexihaler as Bexicap capsule exposed to moisture may not be pierced easily.
Commercial Pack
Azmasol® Bexicap capsule: Box containing 30 capsules in Alu‐Alu blister strips.
Each Azmasol Bexicap capsule contains Salbutamol Sulphate BP equivalent to
Salbutamol 200 mcg.
Manufactured by
Beximco Pharmaceuticals Ltd.
Tongi, Bangladesh 5000295 050511
® Azmasol is a registered trademark of Beximco Pharmaceuticals Ltd.